{"title": "The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2", "doi": "10.1101/2020.03.16.994236", "citation_id": "2020.03.16.994236v1", "date": "2020-03-17", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.03.16.994236", "abstract": "<p>The rapid and escalating spread of SARS coronavirus 2 (SARS-CoV-2) poses an immediate public health emergency, and no approved therapeutics or vaccines are currently available. The viral spike protein S binds ACE2 on host cells to initiate molecular events that release the viral genome intracellularly. Soluble ACE2 inhibits entry of both SARS and SARS-2 coronaviruses by acting as a decoy for S binding sites, and is a candidate for therapeutic and prophylactic development. Using deep mutagenesis, variants of ACE2 are identified with increased binding to the receptor binding domain of S at a cell surface. Mutations are found across the interface and also at buried sites where they are predicted to enhance folding and presentation of the interaction epitope. The N90-glycan on ACE2 hinders association. The mutational landscape offers a blueprint for engineering high affinity ACE2 receptors to meet this unprecedented challenge.</p>", "twitter_description": "The rapid and escalating spread of SARS coronavirus 2 (SARS-CoV-2) poses an immediate public health emergency, and no approved therapeutics or vaccines are currently available. The viral spike protein S binds ACE2 on host cells to initiate molecular events that release the viral genome intracellularly. Soluble ACE2 inhibits entry of both SARS and SARS-2 coronaviruses by acting as a decoy for S binding sites, and is a candidate for therapeutic and prophylactic development. Using deep mutagenesis, variants of ACE2 are identified with increased binding to the receptor binding domain of S at a cell surface. Mutations are found across the interface and also at buried sites where they are predicted to enhance folding and presentation of the interaction epitope. The N90-glycan on ACE2 hinders association. The mutational landscape offers a blueprint for engineering high affinity ACE2 receptors to meet this unprecedented challenge.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.16.994236v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.03.16.994236v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.16.994236v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/03/17/2020.03.16.994236.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.03.16.994236v1", "access_rights": "restricted", "authors": ["Erik Procko"]}